Sensei Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company which focuses on the discovery, development, and delivery of next generation immunotherapies for the treatment of cancer and infectious diseases. The company is headquartered in Rockville, Maryland and currently employs 29 full-time employees. The company went IPO on 2021-02-04. The firm's lead program is PIKTOR, an investigational multi-node inhibitor of the PI3K/AKT/mTOR pathway in development for endometrial and breast cancer. The firm is also completing a Phase I/II trial of solnerstotug, its V-domain Ig suppressor of T cell activation (VISTA) inhibitor, in patients with advanced solid tumors. Its TMAb platform is designed to enable highly selective targeting through conditional antibody activation of immune cells in the tumor microenvironment without on-target, off-tumor activity. Its programs include Solnerstotug (SNS-101), SNS-102, SNS-103, and SNS-201. Solnerstotug is a conditionally active, human monoclonal IgG1 antibody designed to block the VISTA checkpoint, which acts as a suppressor of T cells by binding the receptor PSGL-1.
Mr. Christopher Gerry est le President de Sensei Biotherapeutics Inc, il a rejoint l'entreprise depuis 2025.
Quelle est la performance du prix de l'action SNSE ?
Le prix actuel de SNSE est de $19.67, il a diminué de 0.75% lors de la dernière journée de trading.
Quels sont les thèmes d'affaires principaux ou les industries de Sensei Biotherapeutics Inc ?
Sensei Biotherapeutics Inc appartient à l'industrie Biotechnology et le secteur est Health Care
Quel est la capitalisation boursière de Sensei Biotherapeutics Inc ?
La capitalisation boursière actuelle de Sensei Biotherapeutics Inc est de $26.3M
Est-ce que Sensei Biotherapeutics Inc est un achat, une vente ou un maintien ?
Selon les analystes de Wall Street, 3 analystes ont établi des notations d'analystes pour Sensei Biotherapeutics Inc, y compris 3 achat fort, 3 achat, 2 maintien, 0 vente et 3 vente forte
